Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Top Cited Papers
- 7 February 2006
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 18 (2) , 206-213
- https://doi.org/10.1016/j.coi.2006.01.011
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- THE B7 FAMILY REVISITEDAnnual Review of Immunology, 2005
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- In vivo overexpression of CTLA‐4 suppresses lymphoproliferative diseases and thymic negative selectionEuropean Journal of Immunology, 2005
- Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic MelanomaJournal of Immunotherapy, 2004
- B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological SynapseImmunity, 2004
- CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systemsVaccine, 2004
- Molecular Interactions Mediating T Cell Antigen RecognitionAnnual Review of Immunology, 2003
- Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte ResponsesThe Journal of Experimental Medicine, 2001
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995